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Background: Promotion of endothelial normalization restores tumor oxygenation and obstructs tumor cells
invasion, intravasation, and metastasis. We therefore investigated whether a vasoactive drug, tanshinone IIA, could
inhibit metastasis by inducing vascular normalization after palliative resection (PR) of hepatocellular carcinoma
(HCC).
Methods: A liver orthotopic double-tumor xenograft model in nude mouse was established by implantation of
HCCLM3 (high metastatic potential) and HepG2 tumor cells. After removal of one tumor by PR, the effects of
tanshinone IIA administration on metastasis, tumor vascularization, and survival were evaluated. Tube formation was
examined in mouse tumor-derived endothelial cells (TECs) treated with tanshinone IIA.
Results: PR significantly accelerated residual hepatoma metastases. Tanshinone IIA did not inhibit growth of
single-xenotransplanted tumors, but it did reduce the occurrence of metastases. Moreover, it inhibited PR-enhanced
metastases and, more importantly, prolonged host survival. Tanshinone IIA alleviated residual tumor hypoxia and
suppressed epithelial-mesenchymal transition (EMT) in vivo; however, it did not downregulate hypoxia-inducible
factor 1α (HIF-1α) or reverse EMT of tumor cells under hypoxic conditions in vitro. Tanshinone IIA directly
strengthened tube formation of TECs, associated with vascular endothelial cell growth factor receptor 1/platelet
derived growth factor receptor (VEGFR1/PDGFR) upregulation. Although the microvessel density (MVD) of residual
tumor tissue increased after PR, the microvessel integrity (MVI) was still low. While tanshinone IIA did not inhibit
MVD, it did dramatically increase MVI, leading to vascular normalization.
Conclusions: Our results demonstrate that tanshinone IIA can inhibit the enhanced HCC metastasis associated with
PR. Inhibition results from promoting VEGFR1/PDGFR-related vascular normalization. This application demonstrates
the potential clinical benefit of preventing postsurgical recurrence.
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Surgical resection is the most promising strategy for
early-stage hepatocellular carcinoma (HCC); however,
the 5-year risk of recurrence is as high as 70% [1].
The surgery is actually palliative resection (PR), owing
to the existence of satellites and microvascular inva-
sion, and these residual tumor nests can actually be
stimulated to grow by the PR [2,3]. Although several
treatments, such as interferon-alpha and sorafenib,
have been proposed to diminish relapse [4,5], prometa-
static side effects of these options have also been
observed [6,7].
Residual tumor cells may stimulate angiogenesis,
which is needed for tumor growth [8-10]. However,
the resulting neovessels may be disordered and ineffi-
ciently perfused, resulting in hypoxic conditions
[10,11]. Both abnormal endothelium and pericytes inte-
grated into the capillary wall, along with deficient
coverage, could be responsible for the vascular archi-
tectural abnormalities [12]. The resulting hypoxia cre-
ates a hostile tumor milieu in which tumor cells may
migrate via intra- or extravasation through a leaky ves-
sel [9,13]. In effect, surgery-induced hypoxia unfavor-
ably impacts the prognosis of cancer patients by
inducing angiogenesis [14]. Therefore, restoring oxygen
supply via vascular normalization may reduce metasta-
sis, even tumor growth. Mazzone et al. [13] showed
that downregulation of the oxygen sensing molecule
PHD2 can restore tumor oxygenation and inhibit
metastasis via endothelial normalization, where endo-
thelial cells form a protective phalanx that blocks
metastasis. Although several methods have been shown
experimentally to promote vessel remodeling, only
seldom has any of them found use in the clinic
[9,10,15,16].
Tanshinone IIA (Tan IIA) is an herbal monomer
with a clear chemical structure, isolated from Salvia
miltiorrhiza. In Chinese traditional medicine, S. miltiorrhiza
is considered to promote blood circulation for removing
blood stasis and improve microcirculation. Some of these
effects could include vessel normalization. We have reported
that an herbal formula, Songyou Yin, can attenuate HCC
metastases [17], and S. miltiorrhiza is one of the five consti-
tuents of the formula [18]. Tan IIA exhibits direct vasoactive
[19,20] and certain antitumor properties [21]. It is possible
that Tan IIA may indirectly decrease metastasis in HCC
following PR by promoting blood vessel normalization;
however, there is to date no evidence supporting this
hypothesis.
We aimed to identify inhibitory effects of Tan IIA
on HCC metastasis for delineating a possible mechan-
ism of action of the compound, with a main focus on
tumor vessel maturity as a potential marker for
evaluating Tan IIA treatment responses.Results
PR-induced residual tumor growth and metastasis
As shown in the in vivo experiment 1 (IE 1) in Tables 1
and Additional file 1: Table S2, the tumor volume (TV)
was greater in the PR than Sham groups (p<0.05,
Additional file 1: Figure S1A). Compared with the Sham
group, the lung metastasis (LM) (HCCLM3) of the PR
group significantly increased (p<0.001, Figure 1A and
S1B); both intrahepatic metastasis (IHM) and abdominal
metastasis (AM) also increased (p<0.01 for IHM, in
Figures 1B, Additional file 1: Figure S1C, and Additional
file 1: Figure S2A; p<0.05 for AM, in Figures 1C,
Additional file 1: Figure S1D, and Additional file 1:
Figure S2B); and circulating tumor cells (CTCs) were
elevated both at 2 and 35 d postresection (p<0.001,
Additional file 1: Figure S1E).
Tan IIA does not directly inhibit tumor growth but
reduces metastasis
Results of IE (2), shown in Tables 1 and Additional
file 1: Table S2, indicate there were no differences in
TV between the four groups observed (Additional file 1:
Figure S1A). Compared with normal saline (NS), the LM
of the Tan IIA-treated groups (5 or 10 mg/kg/d) decreased
(p=0.046 and p<0.001, Additional file 1: Figure S1B).
Compared with Tan IIA treatment of 1 or 5 mg/kg/d,
the LM of the 10 mg/kg/d group also decreased
(p=0.003 and p=0.046, Additional file 1: Figure S1B).
Both the IHM and AM rates of the 5/10 mg Tan IIA/kg/d
treatment groups were significantly reduced (p<0.05,
Additional file 1: Figure S1C and D). No AM deriving
from HepG2 cells was found. The greatest inhibitory
effects were seen at a dosage of 10 mg/kg/d, which was
chosen as the intervention dosage in IE (3).
Tan IIA inhibits the PR-enhanced residual tumor
metastasis
Results of IE (3), summarized in Tables 1 and Additional
file 1: Table S2, show that administration of Tan IIA
after PR resulted in decreased residual TV compared to
NS (p<0.05, Additional file 1: Figure S1A). Compared
with the PR + NS group, the LM (HCCLM3) of the Tan
IIA treatment group was significantly decreased
(p<0.001, Figures 1A and Additional file 1: Figure S1B);
both IHM and AM also decreased (p<0.01 for IHM,
Figures 1B, Additional file 1: Figure S1C, and S2A;
p<0.01 for AM, Figures 1C, Additional file 1: Figure S1D,
and S2B), and the CTCs were relatively decreased
(p<0.001, Additional file 1: Figure S1E).
Tan IIA prolongs host survival
Tan IIA treatment retarded the weight loss of mice after
PR (Additional file 1: Figure S3). The estimated survival
of PR mice was significantly shorter than of Sham mice
Table 1 Summary of tumor growth, metastasis, and mice’s survival from three animal experiments of HCCLM3
Items IE (1) IE (2) IE (3)
Sham PR p NS Tan IIA 1 Tan IIA 5 Tan IIA 10 Pb PR+NS PR+Tan
IIA 10
p
TV/cm3 2.712±1.262 5.990±3.113 .014 3.314±0.948 3.643±1.231 3.045±1.031 2.825±0.959 .268 4.736±1.660 3.339±0.924 .047
LM 7.22±4.71 110.11±28.01 .000a 7.42±3.61 6.25±2.77 4.83±3.01 2.25±2.86 .001 94.56±31.47 13.56±11.33 .000
CTCs 0.240±0.082 0.926±0.223 .000 ND ND ND ND – 0.966±0.276 0.283±0.093 .000a
35 d/%
Survival/d 76.833±1.778 51.500±2.784 .000 87.000±3.804 85.500±3.128 96.000±2.658 102.667±3.201 .002 47.833±3.280 69.000±1.693 .001
a Student’s t-test, equal variances assumed.
b One-way analysis of variance.
Abbreviations: PR, palliative resection; NS, normal saline; CTCs, circulating tumor cells; IE, in vivo experiment; LM, lung metastasis; ND, not done; TV, tumor volume.
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Figure 1D). In IE (2), Tan IIA prolonged the mice’s sur-
vival up to 16 d for HCCLM3 (87.000 ± 3.804 vs.
102.667 ± 3.201, p=0.004) and 19 d for HepG2 (p<0.001,
Tables 1 and Additional file 1: Table S2, Figure 1D),
compared with NS. The same effect on prolongation of
post-PR survival was seen in IE (3) (p=0.001 for both,
Tables 1 and Additional file 1: Table S2, Figure 1D).
Tan IIA does not inhibit proliferation but minimizes
invasiveness of tumor cells
Compared with dimethylsulfoxide treatment control, the
OD value of Tan IIA 0.01–100-μM treatment groups
showed no change (Figure 2A). The number of invasiveFigure 1 Schematic diagram of metastases and cumulative survival o
lung (A), intrahepatic (B), and abdomen metastases (C) significantly increas
lesions. (D) Survival curves showed that the life-span of test mice was signi
Red: HCCLM3. Green: HepG2.cells in the 5/10-μM Tan IIA groups was significantly
reduced (p<0.01). No significant differences were seen
for the 1-μM Tan IIA group (Figure 2B and C).
Tan IIA alleviates residual tumor hypoxia in vivo but does
not downregulate HIF-1α of tumor cells under hypoxic
conditions in vitro
The immunohistochemical marker for tissue hypoxia
Pimonidazole and HIF-1α levels were significantly
increased after PR, and they were reduced by Tan IIA. In
addition, the residual tumor epithelial-mesenchymal tran-
sition (EMT) was enhanced (N-cadherin and Vimentin
were both upregulated, but E-cadherin was downregu-
lated), and this effect could be reversed by Tan IIAf tumor-bearing nude mice in animal experiments. Occurrence of
ed after PR. Tan IIA decreased the numbers of various metastatic
ficantly shortened by PR and was markedly prolonged by Tan IIA.
Figure 2 Effects of Tan IIA on tumor cell proliferation and invasion. (A) Tan IIA treatment at 0.01–100 μM did not inhibit HCCLM3 and
HepG2 cell proliferation, except in the 1000-μM dosage group. (B), (C) Tan IIA treatment with 5 or 10 μM for 48 h inhibited tumor cell invasion
(200×).
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These results indicate that PR aggravated residual tumor
hypoxia and promoted EMT, and Tan IIA treatment was
able to alleviate hypoxia and inhibit EMT in vivo. Levels
of HIF-1α, N-cadherin, and vimentin were upregulated
in tumor cells, and E-cadherin was downregulated,
under conditions of hypoxia. Other molecules were not
downregulated as anticipated from results of Tan IIA
experiments in vitro (Figures 3B and Additional file 1:
Figure S4B). We did observe that E-cadherin expression
could indeed be upregulated by Tan IIA, independent of
the hypoxia effect (Figures 3E and Additional file 1:
Figure S4C). Levels of proteins observed were consistent
with their corresponding mRNA levels (Figures 3 and
Additional file 1: Figure S4).
Tan IIA does not affect microvessel density but promotes
microvessel integrity
Studies of mouse microvessel density (MVD) used the
marker CD31. NG2 proteoglycan, the marker of vascularpericytes [12,15], was adopted to evaluate microvessel
intensity (MVI). The CD31 levels of the PR group were
higher than of the Sham (p<0.001), and there was no
statistical significance between the PR + NS and Tan IIA
groups (Figures 4A and Additional file 1: Figure S5A).
Although the NG2 proteoglycan levels showed no
change after PR, its level was significantly elevated in the
PR + Tan IIA group (p<0.01, Figures 4A and Additional
file 1: Figure S5B). Immunohistochemistry of CD31,
NG2, and Pimonidazole in serial sections showed that in
the PR + NS group, CD31 was high, NG2 was low, and
the hypoxia levels (Pimonidazole) were seriously high. In
the PR + Tan IIA group, CD31 was high, NG2 was also
high, and hypoxia levels were slight (Figure 4B). These
results indicate that the residual tumor MVD increased
after PR, but the MVI was low. Tan IIA did not inhibit
MVD but markedly improved MVI, promoting vessel in-
tegrity. Scanning electron microscopy (SEM) further
revealed that the vascular wall of PR + Tan IIA tumors
was more integrated than in the NS tumors (Figure 4C).
Figure 3 Effects of Tan IIA on residual tumor, cell hypoxia and epithelial-mesenchymal transition. (A) PR promoted HIF-1α expression and
caused epithelial-mesenchymal transition (EMT; upregulated N-cadherin and vimentin, downregulated E-cadherin); Tan IIA reversed EMT in vivo.
(B) Hypoxia-induced HIF-1α and promotion of EMT; Tan IIA had no effect on these parameters in vitro. (C), (D) Tan IIA diminished the enlarged
Pimonidazole area of residual tumor after PR (50×). *Compared with Sham group, **compared with PR + NS group; p<0.001. (E) Tan IIA
upregulated E-cadherin in tumor cells (200×).
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did not affect CD31 levels, elevated NG2, and decreased
hypoxia levels (Figure 4D and E).
Tan IIA enhances tube formation and is associated with
vascular endothelial cell growth factor receptor 1
(VEGFR1) and platelet derived growth factor receptor
(PDGFR) upregulation
Tube formation of human umbilical vein endothelial
cells (HUVECs) and human tumor-derived endothelial
cells (TECs) was enhanced by Tan IIA (Figure 5A and B).
And tube formation of TECs from the PR + Tan IIA
(in vivo) mouse group was strengthened relative to the
PR group (Figure 5D). Using TECs from the PR group,we further found that tube formation was enhanced
in vitro by Tan IIA, and it was roughly equivalent to the
PR + Tan IIA (in vivo) group (Figure 5D). Subsequent
flow cytometric analysis of VEGFR1 and PDGFR in
TECs indicated that both the percentage of positive
mice and relative cellular fluorescence intensities
were significantly higher in the PR + Tan IIA group
than the NS group (p<0.05), and no changes were seen
in VEGFR2, EGFR, and FGFR1 levels (Figure 5C). Treat-
ment of cells with the VEGFR1/PDGFR inhibitor
SU6668 weakened the Tan IIA-dependent enhanced
tube formation; whereas, low SU6668 concentration
was not seen to inhibit tube formation without Tan IIA
(Figure 5D).
Figure 4 Effects of Tan IIA on tumor microvessel density, microvessel integrity, and hypoxia. (A) CD31 microvessel density (MVD)
increased, and NG2 microvessel integrity (MVI) showed no change after PR. Tan IIA did not affect MVD, but it did elevate MVI. *p<0.01.
(B) PR + NS group: CD31 was high, NG2 was low, and Pimonidazole was high. PR + Tan IIA group: CD31 was high, NG2 was also high, and thus
hypoxia was slight (400×). (C) The vascular wall of Tan IIA tumor tissue was more integrated than NS tissue (1200×). (D), (E) Tan IIA increased
NG2 levels and reduced residual tumor hypoxia (200×).
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In the present study of postsurgical residual tumors, we
established a double-tumor xenograft HCC model and
found that PR accelerated local aggressivity and distant
metastasis. Administration of Tan IIA after PR signifi-
cantly inhibited metastases and prolonged survival of
nude mice bearing residual tumor tissue, and the effect
was closely associated with VEGFR1/PDGFR-related
vascular normalization.
Early in 1959, Fisher et al. [22] found that partial hepa-
tectomy elicited hepatic metastases. Our results confirm
the view that incomplete surgical resection of primarytumor may well induce the metastatic potential of
residual tumor tissue. Currently, there is no evidence
indicating that presurgical primary tumor could govern
postsurgical residual tumor when growing in the same
liver lobe. Interestingly, we found that residual tumor
hypoxia was aggravated, HIF-1α was upregulated, and
EMT was induced after surgical removal of “primary
tumor.” Van der Bilt et al. [14] have reported that
surgery-induced tumor hypoxia can stimulate abnormal
angiogenesis. Our findings that neovascular abnormality
is significantly augmented following PR are consistent
with that report. Severe tumor hypoxia might have
Figure 5 (See legend on next page.)
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Figure 5 Effects of Tan IIA on endothelial cells tube formation and TEC surface expression of growth factor receptors. (A, B) Tan IIA
enhanced tube formation of HUVECs and human TECs (50×). (C) The percentage of VEGFR1- and PDGFR-positive TECs and the relative
fluorescence intensities. Values were higher in the PR + Tan IIA group than NS group. *p<0.05, **p<0.01. (D) Tube formation was enhanced by Tan
IIA in vivo, similar to results seen with Tan IIA incubation in vitro; the addition of the VEGFR1/PDGFR inhibitor SU6668 weakened this
enhancement effect.
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release of angiogenic cytokines [10], which would en-
hance metastasis.
Tumor vessel abnormalities could promote metastasis
through mechanical penetration and hypoxia-induced
EMT. We selected Tan IIA, known to possess potential
vascular activity, to investigate inhibition of metastasis
and the association with vascular normalization. We
observed that Tan IIA could inhibit post-PR enhanced
metastases and, more importantly, prolong survival. At a
cellular level, Tan IIA showed no effect on tumor cell
proliferation, but it minimized invasion. These effects
were consistent with in vivo results showing that Tan
IIA did not inhibit single-xenograft tumor growth but
decreased metastases. A possible mechanism may be
related by correlation with the observed E-cadherin
upregulation. Furthermore, we observed that Tan IIA
significantly alleviates residual tumor hypoxia and inhi-
bits EMT in vivo. However, it did not downregulate
HIF-1α or reverse EMT of tumor cells under hypoxic
conditions in vitro. Therefore, we propose that the main
inhibition of metastasis by Tan IIA is indirect.
We also observed that the tumor MVD increased after
PR, but the MVI was low, suggesting that the surgery-
induced angiogenesis was related to structural abnor-
malities [14]. Tumor cells would metastasize more easily
through such a leaky vascular wall, causing an increase
of CTCs. Tan IIA did not inhibit MVD but dramatically
improved MVI, which is probably related to its under-
lying vasoactivity. Tan IIA also enhanced tube formation
of endothelial cells under hypoxic conditions in vitro.
Additionally, we found that tube formation of mouse
TECs which processed with Tan IIA no matter in vivo or
in vitro, was similar to each other, further indicating a
direct effect of Tan IIA on endothelium. How Tan IIA
may promote vascular normalization is not entirely clear
because its receptor on endothelial cells is unknown.
Our results have shown a possible correlation with
VEGFR1 and PDGFR upregulation. Recently, it has been
reported that inhibition of VEGFR1 and PDGFR signal-
ing in several tumors causes pericyte detachment and
vessel regression, leading to vascular abnormalities
[23,24]. This implies that upregulation of this signaling
might produce a beneficial effect. Of relevance is the
observation that a compound AZD2171 inhibits VEGFR
while promoting vessel normalization [16]. The mechan-
ism of Tan IIA action requires further investigation.Vascular normalization has effects on two major pro-
cesses: (i) mechanical prevention of tumor cell migra-
tion via intra/extravasation; and (ii) restoration of
oxygen and nutritional supply. However, recovery of
tumor blood supply may have mixed effects by contrib-
uting to progression while also suppressing tumor
growth [9]. The latter effect is likely to depend on a
combination of factors. The normalization of vessels
from both direct and indirect Tan IIA effects appears to
be involved with inhibition of residual tumor growth,
invasion, and metastasis.
Conclusions
Our findings demonstrate that Tan IIA can inhibit the
enhanced metastasis induced by PR and may do so in
part via VEGFR1/PDGFR-related vascular normalization.
This work has an important implication: that the malig-
nant phenotype of a tumor may be manipulated through
vascular pathways, which could be an alternative to sim-
ple eradication. Our results highlight the potential of
proangiogenic “vessel normalizing” treatment strategies
to silence metastasis and prolong patient survival.Methods
Cell lines, animal model, and drug
The human HCC cell lines HCCLM3-RFP, which has
high metastatic potential [25], and HepG2-GFP [26],
HUVECs, and TECs [27] were used in the studies. Male,
athymic BALB/c nu/nu mice of 4–6 weeks of age and
weighing approximately 20 g were used as host animals.
A metastatic human HCC animal model was estab-
lished by orthotopic implantation of histologically intact
tumor tissue into the nude mouse liver [28]. To explore
the protumoral effects of PR, we constructed an orthoto-
pic double-tumor xenograft model, in which two tumor
pieces were simultaneously inoculated into the left liver
lobe; the inoculation method was as described [28].
After 2 weeks, partial hepatectomy [29] was performed
to excise one tumor. The Sham hepatectomy cohort was
handled like the PR cohort, but without tumor resection.
Tan IIA (sulfotanshinone sodium injection, 5 mg/ml),
commercially available from the first Biochemical
Pharmaceutical Co. Ltd., Shanghai, China, was used in
in vivo experiment. Tan IIA monomer (Sigma, St. Louis,
MO), a reddish lyophilized powder with the purity
99.99%, firstly dissolved in dimethyl sulfoxide and then
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in in vitro study.
Experimental groups and assessment parameters
For IE (1), 30 double-tumor-bearing mice were ran-
domly divided into Sham and PR groups (each of n=15)
and scheduled to be observed after 35 d. In IE (2), the
single-tumor xenograft model was used. Mice were
divided into four groups (each n=18) and received daily
injections of NS or Tan IIA (1, 5, or 10 mg/kg/d). Tan
IIA was diluted with NS. We took 20 g as the average
mouse weight (25 g after 21 d), and each mouse received
0.2 mL solution intraperitoneally for 35 d. In IE (3), the
double-tumor xenograft plus PR model was used to
examine effects of Tan IIA on residual tumor. Mice were
divided into two groups (each n=15) after PR and
received daily injections of NS or 10 mg Tan IIA/kg/d
for 35 d.
The mouse weight was measured once every 7 d. After
35 d, six mice from each group were retained to observe
survival, and the remaining were sacrificed to measure
TV [30], LM, IHM, AM [26], CTCs, and to perform
SEM of tumor vessels. CTCs were enumerated by flow
cytometry and expressed as percent CTCs/TV (%) [6].
Twelve mice (IE 1, n = 6) were sacrificed 2 d after resec-
tion to examine CTCs shortly after PR.
Cell proliferation and invasion
A Cell Counting Kit-8 (Dojindo, Kumamoto, Japan) was
used to assay cell proliferation. The final concentration
of Tan IIA was 0.01–1000 μM. Results were expressed
as OD at 490 nm. Cell invasiveness was assayed in
Matrigel-coated Transwell Invasion Chambers (Corning,
Cambridge, MA). Tan IIA was added to cells at final
concentrations of 1, 5, or 10 μM, and these cultures
were incubated for 48 h. Cells that passed through the
chamber membranes were counted.
Hypoxia evaluation
Cells were cultured in a Bugbox Hypoxic Workstation
(Ruskinn, Mid Glamorgan, UK; 1% O2, 5% CO2, and
94% N2 atmosphere) and incubated with Tan IIA at 1, 5,
or 10 μM for 48 h. Normoxic conditions (20% O2, 5%
CO2, and 75% N2) were set as control. Pimonidazole
immunostaining and HIF-1α expression were defined as
hypoxia biomarkers. A Hypoxyprobe™-1 Kit (Hypoxyp-
robe Inc., Burlington, MA) was used [6].
Isolation of TECs, flow cytometry, and tube formation
Eight tumors from Sham, PR, or PR + Tan IIA groups
were collected. The TECs were isolated by use of anti-
CD31 antibody (AB)-coupled magnetic beads (Miltenyi
Biotec, Cologne, Germany) and magnetic cell-sorting
system [27], and they were divided into Sham, PR,PR + Tan IIA (in vivo), and PR + Tan IIA (in vitro)
groups; TECs isolated from the PR group were incu-
bated with Tan IIA for 48 h. TEC surface expression of
VEGFR1, VEGFR2, EGFR, PDGFR, FGFR1, and CD31
was determined by flow cytometric analysis (R&D, Min-
neapolis, MN). Receptor density was calculated as the
relative fluorescence intensity. In another set of experi-
ments, TECs from the PR + Tan IIA (in vivo) cohort
were divided into control and SU6668 (Sigma)
(VEGFR1/PDGFR selective receptor inhibitor) treatment
groups. TECs from the PR cohort were also divided
into PR, PR + SU6668, PR + Tan IIA (in vitro), and
PR + SU6668 + Tan IIA groups. HUVECs and human
TECs were separated into control, normoxia + Tan
IIA, and hypoxia + Tan IIA groups. Formation of
capillary-like structures was observed as described [27].
Immunohistochemistry, immunofluorescence, western
blot, and quantitative real-time polymerase chain
reaction
Immunohistochemistry [31] of Pimonidazole, CD31, and
NG2 [15] was performed in paraffin sections on slides.
The primary antibodies to Pimonidazole (1:100), CD31
(1:100; Abcam, Cambridge, MA), and NG2 (1:200;
Millipore, Billerica, MA) were selected. The integrated
optical density (IOD; for Pimonidazole) or area (for CD31
and NG2) of positive staining/total area was quantified by
Image-Pro Plus software [31]. IF double-staining [31] of
CD31 (1:50) and NG2 (1:50), and NG2 and Pimonidazole
(1:80) was done in frozen sections and observed under
laser confocal microscope. IF of E-cadherin in cells was
also determined.
Protein levels of HIF-1α, N-cadherin, E-cadherin, and
vimentin were determined by immunoblot analysis. Pri-
mary antibodies against HIF-1α (1:1000; Sigma), β-actin,
N-cadherin (1:1000; Abcam), E-cadherin (1:400; Santa
Cruz Biotechnology, Santa Cruz, CA), and vimentin
(1:800; Cell Signaling Technology, Beverly, MA) were
used. Levels of mRNA were assessed by polymerase
chain reaction (Additional file 1: Table S1) and nor-
malized to the corresponding internal β-actin signal
(ΔCt). Relative gene expression values were expressed
as 2−ΔΔCt [30].
Statistical analysis
All statistical analyses were performed with the SPSS
16.0 software. The Pearson chi-square test was applied
to compare qualitative variables. Quantitative variables
were expressed as mean ± standard deviations and ana-
lyzed by t-test or one-way analysis of variance followed
by least significant difference test. The Kaplan–Meier
method with log-rank test was used for survival analysis.
A p value of <0.05 was considered to be statistically
significant.
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Animal care and experimental protocols were approved
by the Shanghai Medical Experimental Animal Care
Commission.
Additional file
Additional file 1: Table S1. The primer sequences for amplification of
human HIF-1α, N-cadherin, E-cadherin, Vimentin, and β-actin. Table S2.
Summary of tumor growth, metastasis, and survival of host mice in three
animal experiments. Figure S1. Statistical chart of tumor volume (A),
metastases to lung (B), intrahepatic (C), and to abdomen (D), and
circulating tumor cells (E) in three animal experiments. *For Student’s t-
test, equal variances were assumed. Abbreviations: CTCs, circulating
tumor cells; IHM, intrahepatic metastasis. Figure S2. Schematic diagram
of intrahepatic and abdomen metastases. (A) Intrahepatic metastatic
lesions were shown by HE staining (50×). (B) Typical abdomen metastasis
of residual HCCLM3 tumor 35 d after palliative resection. Panels a and b
show intrahepatic, peritoneal, and diaphragmatic metastatic lesions. c
and d show intrahepatic and diaphragmatic metastatic lesions; d shows
the area where the tumor in c was removed. Figure S3. Monitoring
body weight of experimental mice in three in vivo experiments. (A) In
vitro experiment 1 (IE 1). (B) IE (2). (C) IE (3). Figure S4. Intratumoral and
intracellular mRNA levels of HIF-1α, N-cadherin, E-cadherin, and Vimentin.
(A) *Compared with Sham group, **compared with PR + NS group;
p<0.05. (B) *Compared with dimethylsulfoxide (DMSO) group,
**compared with hypoxia group; p<0.05. (C) *Compared with DMSO
group; p<0.05. Figure S5. Immunohistochemical staining of CD31 (A)
and NG2 (B) in tumor samples.
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